GoodRx Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GDRX research report →
Range $3.75 – $5
Price Chart
About the company
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing.
- CEO
- Wendy Barnes
- IPO
- 2020
- Employees
- 697
- HQ
- Santa Monica, CA, US
Get TickerSpark's AI analysis on GDRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $996.14M
- P/E
- 63.88
- Fwd P/E
- 9.94
- PEG
- -1.14
- P/S
- 1.46
- P/B
- 1.76
- EV/EBITDA
- 8.13
- Div Yield
- 0.00%
- Gross Margin
- 88.05%
- Op Margin
- 10.25%
- Net Margin
- 2.07%
- ROE
- 2.61%
- ROIC
- 2.64%
Latest fiscal year · YoY change
- Revenue
- $796.85M+0.6%
- Gross Profit
- $739.26M-0.7%
- Op Income
- $87.49M
- Net Income
- $30.44M+85.7%
- EPS
- $0.09+100.9%
- OCF Growth
- -8.7%
- FCF Growth
- +44.8%
- 52W High
- $3.89
- 52W Low
- $1.77
- 50D MA
- $3.44
- 200D MA
- $2.89
- Beta
- 1.67
- RSI (14)
- 31
- Avg Volume
- 1.09M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
GoodRx delivered a strong Q2 with revenue ahead of expectations, led by rapid Pharma Direct growth and expanding subscriptions, and raised full-year guidance.· August 6, 2026
- Q2 revenue was $200.4 million and adjusted EBITDA was $63.7 million, with a 31.8% adjusted EBITDA margin.
- Pharma Direct revenue rose 76% year over year to $61.6 million, helped by consumer-direct pricing programs and GLP-1 access.
- Subscription revenue increased 39% year over year to $28.5 million, while subscription plans grew 14% year over year.
- Prescription transactions revenue was $106.4 million, but monthly active consumers fell to 5 million, down 12% year over year, as the company shifts more users into subscriptions.
- Management raised full-year revenue guidance to $790 million to $805 million and adjusted EBITDA guidance to $240 million to $250 million.
GoodRx reported Q2 revenue of $200.4 million and adjusted EBITDA of $63.7 million, for an adjusted EBITDA margin of 31.8%. Prescription transactions revenue was $106.4 million, Pharma Direct revenue was $61.6 million, and subscription revenue was $28.5 million. Pharma Direct revenue increased 76% year over year, subscription revenue increased 39% year over year, and monthly active consumers were 5 million, down 12% year over year and down sequentially. For the full year, management raised revenue guidance to $790 million to $805 million and adjusted EBITDA guidance to $240 million to $250 million; it also said Pharma Direct revenue is now expected to grow more than 70% year over year. Management said Q3/Q4 should see Pharma Direct and subscriptions more than offset declines in prescription transactions revenue.
Wendy Barnes said the quarter showed GoodRx’s strategy is working, with outperformance in revenue, disciplined profitability, and strong consumer engagement. She emphasized two growth engines: Pharma Direct, which is scaling through manufacturer adoption and GLP-1 access, and subscriptions, which are becoming central to consumer retention through the launch of GoodRx Companion. Her tone was confident but execution-focused, stressing that the company is building a more durable growth profile and that the priority is to keep scaling the programs already in market.
Justin Fengler highlighted Q2 revenue of $200.4 million, adjusted EBITDA of $63.7 million, and a 31.8% margin. He said Prescription transactions revenue of $106.4 million was in line with prior outlook, while Pharma Direct and subscriptions drove the upside: Pharma Direct reached $61.6 million, up 76% year over year, and subscriptions reached $28.5 million, up 39% year over year. He raised full-year revenue guidance to $790 million to $805 million and adjusted EBITDA guidance to $240 million to $250 million, and said the company expects Pharma Direct growth of more than 70% year over year. On capital allocation, he said the first priority is investing in the business, especially subscriptions and pharma, with M&A considered opportunistically.
Analysts focused on how to track the business as GoodRx shifts away from the old MAC-driven model, asking for better operating metrics and visibility into prescription volumes. Management said MACs are not a perfect indicator of success because the company is deliberately moving more users into subscriptions, and said it is still evaluating what new KPIs to provide, with prescription counts among the possibilities. Questions also centered on whether GLP-1s and new launches could sustain Pharma Direct growth, and management said GLP-1s remain important but non-GLP-1 partnerships are also contributing meaningfully. On capital allocation and capacity, management said it does not expect major incremental cost to support Pharma Direct and that cash will primarily be invested back into the business.
The bull case from this call is that GoodRx is successfully diversifying beyond legacy prescription transaction revenue into two faster-growing engines, Pharma Direct and subscriptions. Management sounded confident that GLP-1 demand, expanding manufacturer relationships, and the launch of Companion can support a more durable growth profile and earlier return to year-over-year revenue growth.
The main bear case is that monthly active consumers and prescription transactions are declining as the business shifts, making the transition harder to read using older metrics. Management also acknowledged that Companion is still early, MACs should continue to moderate, and that the company is not yet ready to provide a new core operating KPI, which may leave investors with less visibility in the near term.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.4%
- Shares Outstanding
- 341.15M
- Float Shares
- 280.94M
of shares held by institutions
170 13F filers
Buy/sell ratio 0.56. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GDRX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Anthony GonzalezHouse · OH16 | Buy | Mar 25, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Francisco Partners Management, LP | 52.58M | ▼ 7.50M |
| Vanguard Group Inc | 9.58M | ▲ 376.84K |
| Lsv Asset Management | 5.87M | ▲ 712.18K |
| Ameriprise Financial Inc | 4.75M | ▲ 290.57K |
| Vanguard Capital Management LLC | 4.12M | ▲ 34.79K |
| Silver Lake Group, L.L.C. | 3.53M | 0 |
| Dimensional Fund Advisors LP | 3.38M | ▲ 821.86K |
| Renaissance Technologies LLC | 3.22M | ▼ 27.90K |
| Vanguard Portfolio Management LLC | 3.21M | ▲ 6.56K |
| Petrus Trust Company, Lta | 3.10M | 0 |
| Aqr Capital Management LLC | 2.33M | ▲ 523.74K |
| Arrowstreet Capital, Limited Partnership | 2.28M | ▲ 2.28M |
Held by 135 ETFs
Biggest fund positions in GDRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Chan Thomas (TC) | other | 4,541 |
| Nov 15, 26 | Chan Thomas (TC) | other | 4,541 |
| Nov 15, 26 | Chan Thomas (TC) | other | 2,637 |
| Nov 15, 26 | Chan Thomas (TC) | other | 2,311 |
| Nov 15, 26 | Chan Thomas (TC) | other | 2,637 |
| Nov 15, 26 | Chan Thomas (TC) | other | 1,342 |
| Nov 15, 26 | Chan Thomas (TC) | other | 1,686 |
| Nov 15, 26 | Chan Thomas (TC) | other | 858 |
| Nov 15, 26 | Chan Thomas (TC) | other | 1,686 |
| Nov 15, 26 | Fengler Justin | other | 15,850 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GDRX coverage
Recent articles, reports, and earnings notes.
No research on GDRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GDRX report →GoodRx Brings Prescription Pricing Intelligence to Google Cloud's Gemini for Healthcare
businesswire.com · Nov 10
GoodRx Holdings Is Going Through A Painful Transition That Will Pay Off
seekingalpha.com · Oct 31
GoodRx Launches Employer Direct Weight Loss Offering
businesswire.com · Oct 29
Amazon, GoodRx target US prescription subscribers as health insurance coverage slips
reuters.com · Sep 29
GoodRx Covers Whole Households and Pets in New Prescription Plan
pymnts.com · Sep 4
GoodRx offers health subscription for families, to launch as employee benefit in 2027
reuters.com · Sep 3
From Kids to Canines: GoodRx Launches Companion Family Plan to Bring Healthcare Savings to the Whole Household
businesswire.com · Sep 3
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope
seekingalpha.com · Aug 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.